We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 70% below its sector, cheaper than its peers on earnings.
Jenburkt Pharmaceuticals Ltd. specializes in the creation and commercialization of a wide array of medicinal formulations and healthcare products. Its extensive product range includes treatments for parasitic infestations (anthelmintic), bone density disorders (anti-osteoporotic), joint inflammation (anti-arthritic), stomach ulcers (anti-ulcerants), and bacterial infections (antibiotics). The company also provides aphrodisiacs, remedies for coughs and colds, and dermatological solutions for allergies. Operations are structured into two main divisions: domestic sales and international exports. Jenburkt Pharmaceuticals was founded on June 10, 1985, by Hemendra N. Bhuta, Uttambhai Nandlal Bhuta, and Harshad N. Bhuta, and its corporate headquarters are located in Mumbai, India.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save JENBURPH.BO and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
